Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
03 avr. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae Data to be Presented in Oral Session at...
ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria
14 nov. 2016 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - November 14, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...